Pediatrix Medical Group upgraded by Jefferies with a new price target
$MD
Hospital/Nursing Management
Health Care
Jefferies upgraded Pediatrix Medical Group from Hold to Buy and set a new price target of $14.00 from $8.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/16/2024 | Outperform | Macquarie | |
| 9/26/2024 | $8.00 → $14.00 | Hold → Buy | Jefferies |
| 6/7/2024 | $8.00 | Sell → Hold | Deutsche Bank |
| 2/23/2022 | $32.00 → $31.00 | Outperform | Credit Suisse |
| 12/22/2021 | $33.00 → $32.00 | Outperform | Credit Suisse |
| 11/4/2021 | $29.00 → $27.00 | Market Perform | SVB Leerink |
| 9/27/2021 | $29.00 | Market Perform | SVB Leerink |
| 8/9/2021 | $30.00 → $32.00 | Neutral | Mizuho |
8-K - Pediatrix Medical Group, Inc. (0000893949) (Filer)
10-Q - Pediatrix Medical Group, Inc. (0000893949) (Filer)
8-K - Pediatrix Medical Group, Inc. (0000893949) (Filer)
4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
3 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today announced that its Board of Directors has authorized a share repurchase program of up to $250 million of the Company's outstanding common stock. "In view of our strong cash flow, current and forecasted cash balances and relatively low debt levels, our Board has authorized a $250 million share repurchase program, which we plan to use opportunistically," said Mark S. Ordan, Chair of the Board and Chief Executive Officer. "We will weigh the use of the repurchase program continually against other potential strategic uses of cash to provide the best long-term return to our shareholders and the strongest fu
Raises Full Year 2025 Adjusted EBITDA Outlook Range Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.46 per share for the three months ended June 30, 2025. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.53. For the 2025 second quarter, Pediatrix reported the following results: Net revenue of $469 million; Net income of $39 million; and Adjusted EBITDA of $73 million. "Our second quarter operating results exceeded our forecast and reflect continuing strong neonatology patient volumes, stable payor mix, and careful operations management," said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical
Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, August 5, 2025 at 9:00 a.m. ET to discuss results from operations for the quarter ended June 30, 2025. A detailed press release will be issued the morning of August 5, 2025 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and childre
Macquarie initiated coverage of Pediatrix Medical Group with a rating of Outperform
Jefferies upgraded Pediatrix Medical Group from Hold to Buy and set a new price target of $14.00 from $8.00 previously
Deutsche Bank upgraded Pediatrix Medical Group from Sell to Hold and set a new price target of $8.00
Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today announced that its board of directors has appointed Kurt D. Newman, M.D., former President and Chief Executive Officer of Children's National Hospital in Washington, D.C. and Professor Emeritus of Surgery and Pediatrics at George Washington University School of Medicine and Health Sciences, as an independent director, effective July 1, 2025. Dr. Newman, a surgeon and nationally recognized leader in pediatric healthcare and a long-term healthcare executive, served as President and Chief Executive Officer of Children's National Hospital for 12 years, after spending over 25 years there as a pediatric sur
Executive Chair Mark S. Ordan to Return as Chief Executive Officer Company Redoubles Strategic Focus on Physician Practices and Hospital and Health System Relationships Pediatrix Medical Group, Inc. (NYSE:MD) ("Pediatrix" or "the Company"), a leading provider of physician services, today announced a leadership transition to accelerate its progress in executing a transformational strategy designed to create value for shareholders and other stakeholders. To best position Pediatrix to implement the strategy, which is based on recommitting to the highest standards in clinical excellence and strengthening the Company's hospital relationships, the Company's Board of Directors has appointed Ex
Pediatrix Medical Group, Inc. (NYSE:MD), the nation's leading provider of highly specialized health care for women, children and babies, today announced that its board of directors has appointed Sylvia Young, a recognized leader in healthcare and long-term healthcare executive, as an independent director, effective May 12, 2023. Ms. Young, a veteran of hospital administration since 1985, most recently served as President and CEO of the HCA Continental Division, a multi-state regional healthcare system that is part of Hospital Corporation of America (HCA). Prior to her appointment to the Denver-based Division headquarters, Ms. Young served as President of HCA's Sunrise Health System, inclu
Raises Full Year 2025 Adjusted EBITDA Outlook Range Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.46 per share for the three months ended June 30, 2025. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.53. For the 2025 second quarter, Pediatrix reported the following results: Net revenue of $469 million; Net income of $39 million; and Adjusted EBITDA of $73 million. "Our second quarter operating results exceeded our forecast and reflect continuing strong neonatology patient volumes, stable payor mix, and careful operations management," said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical
Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, August 5, 2025 at 9:00 a.m. ET to discuss results from operations for the quarter ended June 30, 2025. A detailed press release will be issued the morning of August 5, 2025 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and childre
Raises Full Year 2025 Adjusted EBITDA Outlook Range Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.24 per share for the three months ended March 31, 2025. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.33. For the 2025 first quarter, Pediatrix reported the following results: Net revenue of $458 million; Net income of $21 million; and Adjusted EBITDA of $49 million. "Our strong first quarter results reflect same-unit top-line outperformance versus our expectations, continued steady cost management and the successful results of the portfolio restructuring we completed last year. As a result of our strong f
SC 13G - Pediatrix Medical Group, Inc. (0000893949) (Subject)
SC 13G/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)
SC 13G/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)